2-chloro-6-ethylpyridine-4-carboxylic acid | 54881-18-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloro-6-ethylpyridine-4-carboxylic acid
• 英文别名: 2-chloro-6-ethylisonicotinic acid；2-ethyl-6-chloro-isonicotinic acid；2-Aethyl-6-chlor-isonicotinsaeure；2-chloro-6-ethyl-4-pyridinecarboxylic acid
• CAS: 54881-18-4
• 化学式: C₈H₈ClNO₂
• 分子量: 185.61
• InChiKey: SKKSZJCZAOYCDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-6-ethylpyridine-4-carboxylic acid 在 钯 、 溶剂黄146 作用下， 生成 2-乙基-(9ci)-4-吡啶羧酸
  参考文献：
  名称：

  Associations Between Egg Production and Clutch Length in Four Selected Lines of Chickens

  摘要：

  The use of partial records to measure egg production of pedigree breeders has numerous advantages including reduced labor and generation interval. Maintaining egg production in an era where emphasis in breeding programs involves yield and feed conversion presents a challenge to primary breeders. Because breeders obtain individual egg production records, interest in the possibility of using the association of various measures of clutch length with intensity of egg production has been renewed. The correlation of maximum clutch length (prime sequence) throughout lay and during the first 10, 15, and 30 d of lay with percentage hen-day ovulations and normal eggs in four lines (two White Leghorn and two White Plymouth Rock) of chickens during each of 2 yr was measured. Although the rankings of the lines were generally consistent both years for all traits measured, correlations among the sequence lengths with percentage hen-day ovulations and normal eggs were line specific. Thus, poultry breeders would have to determine which of these measures is most appropriate for inclusion with other measures of egg production for each of their specific lines.

  DOI：

  10.1093/japr/11.3.304
• 作为产物：
  描述：

  甲烷-硝酸(1:1) 在 三氯氧磷 作用下， 反应 0.5h， 以2.6 g的产率得到2-chloro-6-ethylpyridine-4-carboxylic acid
  参考文献：
  名称：

  [EN] SULFOXIMINE SUBSTITUTED 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES AND THEIR USE AS CDK9 KINASE INHIBITORS
  [FR] DÉRIVÉS 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE SUBSTITUÉS PAR UN GROUPE SULFOXIMINE ET LEUR UTILISATION COMME INHIBITEURS DE LA CDK9 KINASE

  摘要：

  本发明涉及一种含有亚砜基团的5-氟-N-(吡啶-2-基)吡啶-2-胺衍生物，其通式(I)如所述和定义的那样，并且涉及其制备方法，以及它们用于治疗和/或预防疾病，特别是增殖过度性疾病和/或病毒感染性疾病和/或心血管疾病的方法。本发明还涉及用于制备通式(I)所述化合物的中间体化合物。

  公开号：

  WO2015001021A1

文献信息

• [EN] OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS OXADIAZOLE QUI INHIBENT L'ACTIVITÉ DE LA BÊTA-SECRÉTASE, ET LEURS PROCÉDÉS D'UTILISATION
  申请人：COMENTIS INC

  公开号：WO2012054510A1

  公开（公告）日：2012-04-26

  The invention provides novel beta-secretase inhibitors and methods for their including methods of treating Alzheimer's disease.

  这项发明提供了新型β-分泌酶抑制剂以及它们的方法，包括治疗阿尔茨海默病的方法。
• [EN] SULFOXIMINE SUBSTITUTED 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES AND THEIR USE AS CDK9 KINASE INHIBITORS<br/>[FR] DÉRIVÉS 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE SUBSTITUÉS PAR UN GROUPE SULFOXIMINE ET LEUR UTILISATION COMME INHIBITEURS DE LA CDK9 KINASE
  申请人：BAYER PHARMA AG

  公开号：WO2015001021A1

  公开（公告）日：2015-01-08

  The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper- proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

  本发明涉及一种含有亚砜基团的5-氟-N-(吡啶-2-基)吡啶-2-胺衍生物，其通式(I)如所述和定义的那样，并且涉及其制备方法，以及它们用于治疗和/或预防疾病，特别是增殖过度性疾病和/或病毒感染性疾病和/或心血管疾病的方法。本发明还涉及用于制备通式(I)所述化合物的中间体化合物。
• Organic Compounds
  申请人：Ehara Takeru

  公开号：US20090192148A1

  公开（公告）日：2009-07-30

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I′ wherein R1, R2, T, R3 and R4 areas defined in the specification.

  本发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=失调）；该类化合物用于制备治疗依赖肾素活性疾病的制剂；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的制药配方和/或包括给予3,5-取代哌啶化合物的治疗方法，以及制造3,5-取代哌啶化合物的新型中间体和部分合成步骤。该化合物的式子为I'，其中R1、R2、T、R3和R4在规范中有定义。
• SULFOXIMINE SUBSTITUTED 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES AND THEIR USE AS CDK9 KINASE INHIBITORS
  申请人：BAYER PHARMA AKTIENGESSLL-SCHAFT

  公开号：US20160143893A1

  公开（公告）日：2016-05-26

  The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

  本发明涉及一种含有磺酰亚胺基团的5-氟-N-(吡啶-2-基)吡啶-2-胺衍生物，其一般式（I）如本文所述和定义，以及其制备方法，其用于治疗和/或预防疾病，特别是高增殖性疾病和/或病毒感染性疾病和/或心血管疾病。本发明还涉及在制备所述一般式（I）化合物中有用的中间体化合物。
• Discovery of CH7057288 as an Orally Bioavailable, Selective, and Potent pan-TRK Inhibitor
  作者：Toshiya Ito、Kazutomo Kinoshita、Masaki Tomizawa、Shojiro Shinohara、Hiroki Nishii、Masayuki Matsushita、Kazuo Hattori、Yasunori Kohchi、Masami Kohchi、Tadakatsu Hayase、Fumio Watanabe、Kiyoshi Hasegawa、Hiroshi Tanaka、Shino Kuramoto、Kenji Takanashi、Nobuhiro Oikawa

  DOI：10.1021/acs.jmedchem.2c01099

  日期：2022.9.22

  unique tetracyclic scaffold. Compound 1 showed high TRK selectivity but moderate cell growth inhibitory activity as well as a potential risk of inducing CYP3A4. In this report, chemical modification intended to improve TRK inhibition and avoid CYP3A4 induction enabled us to identify an orally bioavailable, selective, and potent TRK inhibitor 7.

  涉及原肌球蛋白受体激酶 (TRK) 的激酶融合已被证明可作为强大的致癌驱动因子，因此被认为是有吸引力的治疗靶点。我们筛选了一个以激酶为中心的内部库，并确定了一种具有独特四环支架的有希望的命中化合物。化合物1显示出高 TRK 选择性，但具有中等的细胞生长抑制活性以及诱导 CYP3A4 的潜在风险。在本报告中，旨在改善 TRK 抑制和避免 CYP3A4 诱导的化学修饰使我们能够确定一种口服生物可利用的、选择性的和有效的 TRK 抑制剂7。